FFAR1
Free fatty acid receptor 1
Also known as: FFA1R, FFAR1_HUMAN, GPR40
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O14842
- Gene
- FFAR1
- Ensembl
- ENSG00000126266
- Chromosome
- 19
- Canonical length
- 300 aa
- Protein class
- FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters
- Subcellular location
- Plasma membrane
OverviewNCBI Gene
This gene encodes a member of the GP40 family of G protein-coupled receptors that are clustered together on chromosome 19. The encoded protein is a receptor for medium and long chain free fatty acids and may be involved in the metabolic regulation of insulin secretion. Polymorphisms in this gene may be associated with type 2 diabetes. [provided by RefSeq, Apr 2009]
Canonical amino-acid sequenceUniProt
300 residues, UniProt reviewed canonical sequence.
>O14842|FFAR1
1 MDLPPQLSFG LYVAAFALGF PLNVLAIRGA TAHARLRLTP SLVYALNLGC SDLLLTVSLP
61 LKAVEALASG AWPLPASLCP VFAVAHFFPL YAGGGFLAAL SAGRYLGAAF PLGYQAFRRP
121 CYSWGVCAAI WALVLCHLGL VFGLEAPGGW LDHSNTSLGI NTPVNGSPVC LEAWDPASAG
181 PARFSLSLLL FFLPLAITAF CYVGCLRALA RSGLTHRRKL RAAWVAGGAL LTLLLCVGPY
241 NASNVASFLY PNLGGSWRKL GLITGAWSVV LNPLVTGYLG RGPGLKTVCA ARTQGGKSQKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FFAR1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 2.9 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 2.9 nTPM
- ovary: 2.5 nTPM
- pancreas: 2.4 nTPM
- spinal cord: 2.2 nTPM
- hippocampal formation: 1.1 nTPM
- midbrain: 1.1 nTPM
Single-cell type
- pancreatic islet cells: 34 nCPM
- neuroendocrine cells: 7.1 nCPM
- oligodendrocytes: 5.1 nCPM
- granulosa cells: 4.1 nCPM
- b-cells: 3.7 nCPM
- mast cells: 3.4 nCPM
Immune cell
- basophil: 1 nTPM
- neutrophil: 0.4 nTPM
- naive B-cell: 0.1 nTPM
- plasmacytoid DC: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- white matter: 11 nTPM
- cerebral cortex: 5.2 nTPM
- medulla oblongata: 5 nTPM
- basal ganglia: 4.7 nTPM
- pons: 4.6 nTPM
- thalamus: 4.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FFAR1.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 49 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.66
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.61
- DepMap mean gene effect
- -0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- G protein-coupled receptor signaling pathway
- glucose homeostasis
- insulin secretion
- ligand-gated ion channel signaling pathway
- negative regulation of interleukin-1 beta production
- phospholipase C-activating G protein-coupled receptor signaling pathway
- positive regulation of calcium ion transport
- positive regulation of cytosolic calcium ion concentration
- positive regulation of insulin secretion
- response to fatty acid
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FFAR1 as an antibody target. Whether an autoantibody or antibody against FFAR1 could matter depends on whether native FFAR1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FFAR1 is annotated at the cell surface, where native FFAR1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label FFAR1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...